PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1311096
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1311096
Global Fibromyalgia Treatment Market is valued at approximately USD 3.1 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 4.0% over the forecast period 2023-2030. The fibromyalgia treatment market refers to a segment focused on the development and utilization of therapeutic interventions and medications aimed at managing and alleviating the symptoms associated with fibromyalgia, a chronic pain disorder. This market encompasses various treatment modalities, including pharmacological interventions, such as pain medications, antidepressants, and anticonvulsants, as well as non-pharmacological approaches such as physical therapy, cognitive-behavioral therapy, and complementary and alternative therapies. The fibromyalgia treatment market aims to provide effective solutions to improve the quality of life for individuals living with fibromyalgia by reducing pain, improving sleep, managing fatigue, and addressing other associated symptoms. The Fibromyalgia Treatment Market is being driven by factors such as a surge in awareness regarding fibromyalgia and its treatment and Enhanced access to generic medications for fibromyalgia treatment.
Fibromyalgia treatment involves a multidimensional approach aimed at managing the symptoms and improving the quality of life for individuals with fibromyalgia. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, approximately five million individuals aged 18 years or over in the U.S. suffer from fibromyalgia. Additionally, over 80-90 %of fibromyalgia patients are female. Along with that Lupin has received FDA approval on May 2022, for its generic Pregabalin Capsules, a substitute for Lyrica Capsules used to treat neuropathic pain, fibromyalgia, and epilepsy. The capsules, available in various strengths, will be manufactured in Lupin's Aurangabad facility in India. This approval allows Lupin to offer a more affordable alternative to Lyrica, expanding access to essential medication in the United States. Thus, these fibromyalgia cases and increasing FDA approvals fuel the growth of the market. In addition to Robust pipeline of products for fibromyalgia treatment and the development of novel therapies may create lucrative opportunities for the market. However, the availability of alternative treatment options may hinder the growth of the market throughout the forecast period of 2023-2030.
The key regions considered for the Global Fibromyalgia Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to an increase in the high prevalence of Fibromyalgia in the region, with a significant number of individuals affected by the chronic pain condition and advancements in treatment options. Asia Pacific is considered the fastest growing region during the forecasted period due to increasing investment in healthcare facility and advancement in healthcare technologies.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
List of tables and figures are dummy in nature, final lists may vary in the final deliverable
List of tables and figures are dummy in nature, final lists may vary in the final deliverable